| coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene-induced senescence | None |
| The prevalence of oncogenic RAS mutations was higher among Arab Asian children than in other countries. RAS mutations in AML were found to coexist with other genetic aberrations, particularly MLL rearrangement | None |
| Data show that small molecule protein kinase inhibitor DEL-22379 blocks proliferation of tumor cells harboring RAS-ERK pathway oncogenes. | None |
| NF2/merlin inactivation augments mutant RAS signaling by promoting YAP/TEAD-driven transcription of oncogenic and wild-type RAS, resulting in greater MAPK output and increased sensitivity to MEK inhibitors. | None |
| GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B | None |
| GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site. | None |
| Data show that RAS protein activation was the initiating oncogenic event, with polycomb repressive complex 2 (PRC2) subunits impairment being a secondary event. | None |
| Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation. | None |
| A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations. | None |
| Beneficial effects of low dose radiation in response to the oncogenic KRAS induced cellular transformation. | None |
| Data indicate that tumors with proto-oncogene proteins BRAF or KRAS mutations were in correlation with elevated serum level of carbohydrate antigen (CA19-9) and carcinoma embryonic antigen (CEA). | None |
| Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. | None |
| Comparison of the computed structures for the phosphate-binding loop of the p21 protein containing the oncogenic site Gly 12 with the X-ray crystallographic structures for this region in the p21 protein and EFtu. A model for the structure of the p21 protein in its oncogenic form. | None |
| Immunoprecipitation of cell lysates with RAP-5 does not specifically detect ras oncogene product p21. | None |
| Molecular dynamics simulations help provide a mechanistic explanation of key mutational events in one of the most oncogenic proteins in cancer, KRAS-4B. | None |
| ras p21 oncoprotein is autoregulated and acts as a potential mediator of insulin action or the H-ras1 promoter. | None |
| oncogenic mutant K-Ras interacts with a negatively charged lipid bilayer membrane in multiple orientations. | None |
| demonstrate the tumor suppressor function of WT Kras in oncogenic Kras-induced leukemogenesis and elucidate its underlying cellular and signaling mechanisms. | None |
| Binase-KRAS interaction interferes with the function of GEFs and stabilizes the inactive GDP-bound conformation of RAS thereby inhibiting MAPK/ERK signaling and oncogenic activity. | None |
| This study reveals KRAS(G12D) uniquely regulates tumor cells via heterotypic stromal cells. By exploiting heterocellularity, reciprocal signaling enables KRAS(G12D) to engage oncogenic signaling pathways beyond those regulated in a cell-autonomous manner. | None |